Twinbeech Capital LP Buys 41,840 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Twinbeech Capital LP boosted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 1,584.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,480 shares of the medical research company's stock after buying an additional 41,840 shares during the period. Twinbeech Capital LP owned approximately 0.09% of Charles River Laboratories International worth $8,211,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. Vanguard Group Inc. grew its stake in Charles River Laboratories International by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company's stock valued at $1,136,938,000 after buying an additional 60,497 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Charles River Laboratories International by 9.0% during the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock valued at $752,508,000 after purchasing an additional 335,658 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Charles River Laboratories International by 2.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock valued at $330,231,000 after purchasing an additional 47,221 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Charles River Laboratories International by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock valued at $227,042,000 after purchasing an additional 14,787 shares in the last quarter. Finally, Ariel Investments LLC grew its position in shares of Charles River Laboratories International by 18.9% during the 4th quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company's stock valued at $197,029,000 after purchasing an additional 169,640 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Morgan Stanley reduced their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 5th. JPMorgan Chase & Co. reduced their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research report on Thursday, February 20th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and reduced their price target for the company from $188.00 to $182.00 in a research report on Friday. Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Finally, Robert W. Baird boosted their price target on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International has a consensus rating of "Hold" and a consensus price target of $171.85.

Charles River Laboratories International Trading Up 0.9%

Charles River Laboratories International stock traded up $1.16 during mid-day trading on Friday, hitting $136.76. The company's stock had a trading volume of 775,603 shares, compared to its average volume of 993,966. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The stock has a market cap of $6.72 billion, a price-to-earnings ratio of 911.73, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. The business has a 50 day moving average price of $132.05 and a 200-day moving average price of $163.10. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping the consensus estimate of $2.06 by $0.28. The business had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm's revenue for the quarter was down 2.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.27 earnings per share. As a group, analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the transaction, the executive vice president now directly owns 19,513 shares of the company's stock, valued at approximately $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.30% of the stock is currently owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).